Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 11066475
    Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 20, 2021
    Assignees: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. Sather, Eric L. Smith, Rupesh Amin, Aye Chen, Kimberly Harrington, Collin Hauskins, Erik Hess, Cyr De Imus, Jon Jones, Audrey Olshefsky, Stefan Ponko, Ruth Salmon, Semih Tareen, Rebecca Wu, Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons, Mariana Cota Stirner, Melissa Works
  • Patent number: 11065239
    Abstract: This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 20, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Ke Ma, Guoqing Cao, Changyong Yang, Lianshan Zhang
  • Patent number: 11058769
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
  • Patent number: 11059898
    Abstract: Through a combination of in vitro and in vivo approaches, the inventors show that human IgG2 (h2) delivers unique Fc?R-independent agonistic activity to anti-CD40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1BB and CD28. Investigation of an anti-human CD40 mAb, LOB7.4, revealed that the unique activity of h2 was dependent upon the precise arrangement of hinge and CH1 disulfide bonds. Chemical ‘shuffling’ or mutagenesis to ‘lock’ LOB7.4 into either a more flexible ‘h2A’ or more compact ‘h2B’ conformation endowed antagonistic and agonistic properties, respectively. Engineering of h2 in this way allows development of reagents with either immunostimulatory or immunosuppressive characteristics, with direct implication for the design of therapeutic mAb agents and fusion proteins.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: July 13, 2021
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Martin J. Glennie, Ann White
  • Patent number: 11060092
    Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 13, 2021
    Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, RAMBAM MED-TECH LTD.
    Inventors: Izhak Kehat, Alon Abend, Omer Shkedi, Lilac Caspi
  • Patent number: 11059909
    Abstract: Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 13, 2021
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers, Geert Jan Van Tetering
  • Patent number: 11060150
    Abstract: This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having ER?/PgR?/HER2? cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor are provided. Methods and materials involved in treating mammals having ER?/PgR?/HER2? cancer (e.g., ER?/PgR?/HER2? breast cancer) by administering a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor also are provided.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 13, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Barbara A. Pockaj, Michael T. Barrett, Mitesh J. Borad, Karen S. Anderson, Ramesh K. Ramanathan
  • Patent number: 11059911
    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Patent number: 11059892
    Abstract: In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
    Type: Grant
    Filed: August 11, 2018
    Date of Patent: July 13, 2021
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee, Tae Hyun Kang
  • Patent number: 11058776
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: July 13, 2021
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 11058752
    Abstract: The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed IgG1, CD40L, TNF-alpha, as well as membrane and soluble forms of GM-CSF, and Flt-3L peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 13, 2021
    Assignee: ALLOPLEX BIOTHERAPEUTICS
    Inventor: Frank Borriello
  • Patent number: 11053318
    Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 6, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Peter Kufer, Roman Kischel, Marion Subklewe, Christina Heitmueller
  • Patent number: 11053543
    Abstract: Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: July 6, 2021
    Assignee: GigaGen, Inc.
    Inventors: David Scott Johnson, Everett Hurteau Meyer
  • Patent number: 11045547
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
  • Patent number: 11047864
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 29, 2021
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • Patent number: 11046771
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: June 29, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Patent number: 11046741
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 29, 2021
    Assignees: Salubris Biotherapeutics, Inc., Salubris (Chengdu) Biotech Co., Ltd.
    Inventors: John Li, Shengwei Li, Dixiang Luo, Yiran Wu, Ming Zhou, Xiaolei Zhuang, Liang Hua, Pengyi Luo, Yang Wang
  • Patent number: 11046778
    Abstract: The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: June 29, 2021
    Assignees: TOHOKU UNIVERSITY, ZENOAQ RESOURCE CO., LTD.
    Inventors: Yukinari Kato, Mika Kato, Satoshi Ogasawara
  • Patent number: 11046755
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 29, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Huilai Tian
  • Patent number: 11041861
    Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 22, 2021
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Joël Jean-Mairet
  • Patent number: 11034760
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 15, 2021
    Assignee: Swedish Orphen Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Patent number: 11034763
    Abstract: The present invention provides chimeric antigen receptor (CAR)-T cells modified to express a CAR fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen CD19, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the fusion protein further comprises a FLAG tag N-terminus to scFv, C-terminus to scFv, or between VH and VL. Using CD19-FLAG CAR-T cells instead of CD19 CAR-T cells, cytokine levels (Interferon-?, IL-2 and IL6) caused by infused CAR-T cells are reduced.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 15, 2021
    Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd.
    Inventors: Lijun Wu, Vita Golubovskaya, Martyn Lewis, Hua Zhou
  • Patent number: 11033636
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 15, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • Patent number: 11034748
    Abstract: The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human MAGE-A1 epitopes), T cells expressing such high affinity antigen-specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 15, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Aude Chapuis, Thomas Schmitt, Megan McAfee
  • Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Patent number: 11034681
    Abstract: Disclosed are a crystal form of an indole derivative (compound 1) and a pharmaceutical composition and preparation method thereof. The crystal form is used to prepare a drug for treating a disease related to a CRTH2 receptor.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: June 15, 2021
    Inventors: Yuanshan Yao, Bin Chen, Feng Gao, Yuan Chen, Ran Xu, Chengshuai Yang, Sheng Zhang, Jian Li, Shuhui Chen
  • Patent number: 11034764
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: June 15, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • Patent number: 11028165
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 8, 2021
    Assignee: MORPHOSYS AG
    Inventors: Stefan Steidl, Elisabeth Thomassen-Wolf
  • Patent number: 11022614
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: June 1, 2021
    Assignee: UCB Biopharma SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Tracy Lynn Arakaki, Daniel John Lightwood, Rebecca Jayne Munro
  • Patent number: 11022615
    Abstract: The invention pertains to methods of isolating a Treg from a subject, the method comprising the steps of analyzing a sample of cells obtained from the subject to determine the level of expression of polypeptides and/or polynucleotides corresponding to proteins CD 127, CD4, CD25, and CD226 and isolating, as the Treg, a cell which expresses CD4 and CD25, expresses low levels of CD 127 or does not express CD 127, and expresses low levels of CD226 or does not express CD226. The Treg isolated from a subject can be proliferated in vitro. Accordingly, the invention also provides compositions comprising Treg isolated/proliferated according to the methods of the invention and pharmaceutically acceptable carrier and/or excipient. The pharmaceutical compositions can be used to treat and/or prevent inflammation mediated disease, for example, autoimmune diseases, such as, systemic lupus erythmatosus, rheumatoid arthritis, Multiple Sclerosis, type 1 diabetes, or inflammatory bowel disease.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: June 1, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Todd M. Brusko, Christopher Fuhrman, Howard R. Seay
  • Patent number: 11014985
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 25, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Patent number: 11008399
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • Patent number: 11000588
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 11001633
    Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 11, 2021
    Assignee: Affimed GmbH
    Inventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
  • Patent number: 11001819
    Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: May 11, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshirou Kawaguchi, Kensuke Nakamura, Yukiko Sekiguchi, Mitsuhiro Iwamoto
  • Patent number: 11001632
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 11, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • Patent number: 10994021
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: May 4, 2021
    Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
    Inventors: Yuhong Zhou, Ziping Wei
  • Patent number: 10993942
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 4, 2021
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Patent number: 10988546
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: April 27, 2021
    Assignee: MedImmune, LLC
    Inventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
  • Patent number: 10981998
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3? (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: April 20, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffman, Matthias Klinger, Doris Rau, Susanne Mangold
  • Patent number: 10981953
    Abstract: A method for promoting expression of calreticulin in at least one kind of eukaryotic cell, and a synthetic peptide useful in this method are provided. In the method provided by the present invention, a culture of target cells is prepared, and a calreticulin expression-promoting peptide having calreticulin expression-promoting activity is supplied at least once to that culture.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 20, 2021
    Assignees: TOAGOSEI CO, LTD., KYOTO UNIVERSITY
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Yoshinori Yoshida, Kazuhisa Chonabayashi
  • Patent number: 10980866
    Abstract: Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (AAT) deficiency, the method comprising administering to the subject a therapeutically effective amount of AAT.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 20, 2021
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Yaron Ilan
  • Patent number: 10980835
    Abstract: The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 20, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 10973772
    Abstract: A method of designing a pharmaceutical composition for providing the liver of a person or animal, as a therapeutic target, with a predetermined concentration of a sulfate or sulfonate of a pharmacologically active agent, during a predetermined period, includes determining the correlation between the solubility of a sulfate and/or sulfonate of a pharmacologically active agent of the formula Dn+(R1SO3)?n or Dn+(R2OSO3)?n for various carbon chain lengths X, Y in an aqueous solvent and the expected concentration of the pharmaceutically active agent D in the therapeutic target upon administration of the pharmacologically active agent D to the person or animal, defining a target solubility of the sulfate or sulfonate based on a desired concentration of said pharmaceutically active substance D in the therapeutic target, and determining the carbon chain length(s) X, Y corresponding to the target solubility.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 13, 2021
    Assignee: DOUBLE BOND PHARMACEUTICALS AB
    Inventor: Igor Lokot
  • Patent number: 10973799
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: April 13, 2021
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • Patent number: 10968431
    Abstract: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: April 6, 2021
    Assignees: City of Hope, Fred Hutchinson Cancer Research Center
    Inventors: Stanley R. Riddell, Susanna Carolina Berger, Michael C. Jensen
  • Patent number: 10961311
    Abstract: The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: March 30, 2021
    Assignee: MACROGENICS, INC.
    Inventors: Deryk T. Loo, Ling Huang, Leslie S. Johnson, Thomas Son, Juniper A. Scribner, Ezio Bonvini
  • Patent number: 10954302
    Abstract: Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: March 23, 2021
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Keyt, Leonard George Presta, Ramesh Baliga
  • Patent number: 10954500
    Abstract: Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: March 23, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Rupesh Amin
  • Patent number: 10945990
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.
    Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak